Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 7/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17739557 | 0.87 | METAP2 (0.46) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL16675976 | 0.83 | METAP2 (0.49) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL17739208 | 0.81 | IDO1 (0.47) | METAP2IDO1TDO2 | |
| SCHEMBL17738663 | 0.78 | METAP2 (0.44) | METAP2IDO1NOS1DYRK1ATDO2 | |
| SCHEMBL21894754 | 0.77 | IDO1 (0.39) | METAP2IDO1TDO2 | |
| SCHEMBL17739210 | 0.75 | METAP2 (0.55) | METAP2IDO1TDO2 | |
| SCHEMBL17738420 | 0.74 | IDO1 (0.47) | METAP2IDO1TDO2 | |
| SCHEMBL30604481 | 0.74 | IDO1 (0.47) | METAP2IDO1TDO2 | |
| SCHEMBL22864073 | 0.74 | ADRB2 (0.45) | METAP2IDO1TDO2 | |
| SCHEMBL20001903 | 0.74 | METAP2 (0.38) | METAP2IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| WO-2016071293-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | METAP2 840/4885IDO1 1/4885NOS1 336/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | METAP2 840/4885IDO1 1/4885NOS1 336/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | METAP2 840/4885IDO1 1/4885NOS1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.